Fellowship in the BTC |
Spine Tumor Clinic|
BTC Web |
Brain Tumor Center|
Brain Tumor Research|
(Neurology – University of Washington, Seattle)
(Neurology – Mayo Clinic)
Uhlmann, M.D., Ph.D.
(Neurology, University of Minnesota)
Year (Clinical Rotations)
Dietrich, M.D., Ph.D.
(Neurology - Partners Neurology Residency Program)
(Neurology – University of California, Los Angeles
(Neurology – Partners Neurology Program)
Research Project: Identification of biomarkers in
Sponsor: Cathy Nutt, Ph.D.
first year of the fellowship is devoted to an intensive
exposure to clinical neuro-oncology. Each trainee
gains extensive experience in the full spectrum
of diseases and problems encountered in neuro-oncology.
Three first year fellows rotate between the neuro-oncology
services at Massachusetts General Hospital and the
Dana Farber Cancer Institute. Two fellows at MGH
rotate on the inpatient (hospital) and outpatient
(clinic) departments at a given time; one fellow
rotates on the combined inpatient/outpatient at
DFCI. There is comprehensive training and experience
in the administration of chemotherapy and management
of chemotherapy complications.
hospital rotation includes management of patients
on the neuro-oncology service and neuro-oncology
consultations requested by other services (oncology,
medicine, neurology, neurosurgery). In 2000 there
were approximately 400 admissions to the neuro-oncology
service at MGH and 400 consultations. Fellows work
closely each month with the attending neuro-oncologist
assigned to the service and one of two neuro-oncology
nurse practitioners who also rotate between the
inpatient and outpatient services each month. All
patients are admitted to the Raymond D. Adams (RDA)
Neurology Service and are managed in collaboration
with neurology residents and Harvard Medical School
clinic rotation includes attending several neuro-oncology
staff clinics each week and preparation of the weekly
neuro-oncology clinical conference. The outpatient
neuro-oncology nurse practitioner, senior neurology
residents and Harvard Medical School students also
participate in these clinics.
completion of the clinical year fellows embark on
1-2 years of additional research training. Both
clinical and laboratory research tracks are possible
as well as a translational track which combines
both clinical and laboratory training. Fellows can
receive formal training in clinical research methodology
through the Program in Clinical Effectiveness at
the Harvard School of Public Health. Each trainee
selects a research mentor who is responsible for
specific projects and the educational development
of the trainee.
Neuro-Oncology Training Program at the Massachusetts
General Hospital has a National Cancer Institute
training grant (K12 award), "Clinical Research
Training Program in Neuro-Oncology". This recent
award will foster translational research training
for neuro-oncology fellows at the Massachusetts
General Hospital. Tracy Batchelor, M.D., Director
of Neuromedical Oncology is the Director for this
grant. Research mentors for the grant were chosen
from the MGH, Brigham and Women's Hospital, Dana-Farber
Cancer Institute, Harvard Medical School and the
Harvard School of Public Health. All trainees will
be admitted to the Program in Clinical Effectiveness
at the Harvard School of Public Health and will
spend two 7-week summer periods engaged in a full
time curriculum in clinical research methodology.
Trainees are encouraged to apply for admission to
HSPH and may earn the Master of Science or Master
of Public Health degree upon completion of the fellowship
and degree requirements.
Neuro-Oncology Training Program at the Massachusetts
General Hospital welcomes applications from graduates
of training programs in neurology, hematology/oncology,
pediatric oncology, neurosurgery and radiation oncology.
Two trainees are accepted each year with clinical
rotations starting in July. Applicants are required
to submit a letter of interest, curriculum vitae and
three letters of recommendation to:
R. Plotkin, M.D., Ph.D.
Pappas Center for Neuro-Oncology
Massachusetts General Hospital
55 Fruit Street, Yawkey 9E
Boston, Massachusetts 02114
should submit material between January 1 and April
30 in the year prior to starting the fellowship.
Interested individuals may elect a visiting rotation
on our service in the year prior to applying for the
fellowship. A minimum of three months is required
to arrange for this rotation. Contact the above address
for more information.
Fellow Abstracts and Publications:
Quant, A. D. Norden, J. Drappatz, A. Ciampa, L. Doherty,
D. LaFrankie, S. Kesari and P. Y. Wen, J. Role of
a second chemotherapy in recurrent malignant glioma
patients who progress on a bevacizumab-containing
regimen, . Clin. Oncol, Vol 26, No 15S (May 20 Supplement),
Sun PC, Uppaluri R, Schmidt AP, Pashia ME, Quant EC,
Sunwoo JB, Gollin SM, Scholnick SB. Transcript map
of the 8p23 putative tumor suppressor region. Genomics.
Dietrich J, Imitola J, Kesari S. Mechanisms of Disease:
the role of stem cells in the biology and treatment
of gliomas. Nat Clin Pract Oncol. 2008 Jul;5(7):393-404.
Schneider JP, Trantakis C, Rubach M, Schulz T, Dietrich
J, Winkler D, Renner C, Schober R, Geiger K, Brosteanu
O, Zimmer C, Kahn T. Intraoperative MRI to guide the
resection of primary supratentorial glioblastoma multiforme--a
quantitative radiological analysis. Neuroradiology.
Hau P, Fabel K, Baumgart U, Rümmele P, Grauer
O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel
C, Hübner F, Jauch T, Drechsel E, Kleiter I,
Wismeth C, Zellner A, Brawanski A, Steinbrecher A,
Marienhagen J, Bogdahn U. Pegylated liposomal doxorubicin-efficacy
in patients with recurrent high-grade glioma. Cancer.
2004 Mar 15;100(6):1199-207.
Noble M, Dietrich J. The complex identity of brain
tumors: emerging concerns regarding origin, diversity
and plasticity. Trends Neurosci. 2004 Mar;27(3):148-54.
Hau P, Baumgart U, Pfeifer K, Bock A, Jauch T, Dietrich
J, Fabel K, Grauer O, Wismeth C, Klinkhammer-Schalke
M, Allgäuer M, Schuierer G, Koch H, Schlaier
J, Ulrich W, Brawanski A, Bogdahn U, Steinbrecher
A. Salvage therapy in patients with glioblastoma:
is there any benefit? Cancer. 2003 Dec 15;98(12):2678-86.
the Specialized Care of Individuals with Brain
Brain Tumor Center
Yawkey Building 9th Floor
Boston, Massachusetts, 02114
& Families with questions about referrals, consultations
or appointments may contact:
questions may contact:
Tracy Batchelor, M.D.
MGH Brain Tumor Center